119 related articles for article (PubMed ID: 3455613)
1. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
Vega E; Gonzalez D; Ghiringhelli G; Mautalen C
J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
[TBL] [Abstract][Full Text] [Related]
2. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Chakravarty K; Merry P; Scott DG
J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
[TBL] [Abstract][Full Text] [Related]
3. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
4. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
5. The effects of intravenous alendronate in Paget's disease of bone.
O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
7. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
Thiébaud D; Jaeger P; Burckhardt P
J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
10. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
11. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
12. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
15. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
O'Doherty DP; Gertz BJ; Tindale W; Sciberras DG; Survill TT; Kanis JA
J Bone Miner Res; 1992 Jan; 7(1):81-7. PubMed ID: 1549961
[TBL] [Abstract][Full Text] [Related]
16. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
17. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
Vega E; Mautalen C; Roldán EJ; Pérez Lloret A
Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716
[TBL] [Abstract][Full Text] [Related]
19. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
[TBL] [Abstract][Full Text] [Related]
20. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
